연구동향 분석

Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation

Keun-Sik Hong 2019년

논문상세정보
인용/피인용
' Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Acute coronary syndrome
  • Atrial fibrillation
  • Stroke
  • anticoagulants
  • cardiovasculardiseases
  • venous thromboembolism
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,688 0

0.0%

' Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation' 의 참고문헌

  • Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis
    Schulman S [2014]
  • The AtRial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke randomized trial: rationale and methods
    Kamel H [2019]
  • Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial
    Fuji T [2014]
  • Rivaroxaban with or without aspirin in stable cardiovascular disease
  • Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
    Anand SS [2018]
  • Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
    Pengo V [2018]
  • Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    Patel MR [2011]
  • Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
    Mega JL [2009]
  • Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
    Turpie AG [2009]
  • Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
    Lassen MR [2008]
  • Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
    Eriksson BI [2008]
  • Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial
    Kasner SE [2018]
  • Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease
    Zannad F [2018]
  • Rivaroxaban in patients with a recent acute coronary syndrome
    Mega JL [2012]
  • Rivaroxaban for thromboprophylaxis in acutely ill medical patients
    Cohen AT [2013]
  • Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies
    Turpie AG [2011]
  • Rivaroxaban for stroke prevention after embolic stroke of undetermined source
    Hart RG [2018]
  • Risk-benefit profile of warfarin versus aspirin in patients with heart failure and sinus rhythm: a meta-analysis
    Lee M [2013]
  • Rationale, design, and protocol of a randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous thrombosis
    Ferro JM [2018]
  • Prevention of bleeding in patients with atrial fibrillation undergoing pci
    Gibson CM [2016]
  • Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
  • Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    Kahn SR [2012]
  • Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke
    Mas JL [2017]
  • Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
  • Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
  • Oral rivaroxaban for symptomatic venous thromboembolism
  • Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients
  • Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATEII*): a randomised, double-blind, non-inferiority trial
    Eriksson BI [2011]
  • Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial
    Eriksson BI [2007]
  • Oral apixaban for the treatment of acute venous thromboembolism
    Agnelli G [2013]
  • Novel factor Xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients
  • New Oral Anticoagulants versus Warfarin for Cerebral Venous Thrombosis: A Multi-Center, Observational Study
  • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): cancer-associated venous thromboembolic disease version 1
  • Malignancies, prothrombotic mutations, and the risk of venous thrombosis
    Blom JW [2005]
  • Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction
  • Inflammation, fibrinogen and thrombin generation in patients with previous myocardial infarction
    Réganon E [2002]
  • Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial
    Hull RD [2010]
  • Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban)
    Gibson CM [2017]
  • Extended use of dabigatran, warfarin, or placebo in venous thromboembolism
    Schulman S [2013]
  • Extended thromboprophylaxis with betrixaban in acutely ill medical patients
    Cohen AT [2016]
  • Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial
    Kakkar AK [2008]
  • Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial
    Vranckx P [2018]
  • European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis: endorsed by the European Academy of Neurology
    Ferro JM [2017]
  • Embolic strokes of undetermined source: the case for a new clinical construct
    Hart RG [2014]
  • Efficacy and safety of rivaroxaban versus aspirin in embolic stroke of undetermined source and carotid atherosclerosis
    Ntaios G [2019]
  • Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V
    Fuji T [2015]
  • Edoxaban versus warfarin in patients with atrial fibrillation
  • Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism
  • Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials
    Kawai Y [2016]
  • Edoxaban for the treatment of cancer-associated venous thromboembolism
    Raskob GE [2018]
  • Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation
    Cannon CP [2017]
  • Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association
    Saposnik G [2011]
  • Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function
    Mazzolai L [2018]
  • Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial
    Oldgren J [2011]
  • Dabigatran versus warfarin in the treatment of acute venous thromboembolism
    Schulman S [2009]
  • Dabigatran versus warfarin in patients with atrial fibrillation
    Connolly SJ [2009]
  • Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials
    Friedman RJ [2010]
  • Dabigatran therapy in acute ischemic stroke patients without atrial fibrillation
    Kate M [2015]
  • Dabigatran for prevention of stroke after embolic stroke of undetermined source
    Diener HC [2019]
  • Dabigatran following acute transient ischemic attack and minor stroke II (DATAS II)
    Ng KH [2017]
  • Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
    Eriksson BI [2007]
  • Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)
    Young AM [2018]
  • Coagulation activation and long-term outcome in acute coronary syndromes
    Ardissino D [2003]
  • Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
    Ohman EM [2017]
  • Association of rivaroxaban with thromboembolic events in patients with heart failure, coronary disease, and sinus rhythm: a post hoc analysis of the COMMANDERHF Trial
    Greenberg B [2019]
  • Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial
    McBane RD [2018]
  • Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial
  • Apixaban with antiplatelet therapy after acute coronary syndrome
  • Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients
  • Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised doubleblind trial
    Lassen MR [2010]
  • Apixaban versus enoxaparin for thromboprophylaxis after hip replacement
    Lassen MR [2010]
  • Apixaban or enoxaparin for thromboprophylaxis after knee replacement
    Lassen MR [2009]
  • Apixaban in patients with atrial fibrillation
    Connolly SJ [2011]
  • Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): rationale and study design
    Geisler T [2017]
  • Apixaban for the treatment of cerebral venous thrombosis: a case series
    Rao SK [2017]
  • Apixaban for extended treatment of venous thromboembolism
    Agnelli G [2013]
  • Apixaban and dalteparin in active malignancy associated venous thromboembolism: the ADAM VTE trial
    McBane Ii R [2017]
  • Antithrombotic therapy for VTE disease : CHEST guideline and expert panel report
    Kearon C [2016]
  • Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation
    Lopes RD [2019]
  • 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
    January CT [2019]
  • 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)
    Lip GYH [2019]
  • 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation : the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC)
    Ibanez B [2018]
  • 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
    Kirchhof P [2016]
  • 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines